Democritus University of Thrace (DUTH)
Συσχέτιση του βαθμού βαρύτητας της περιοδοντικής νόσου με τον αποικισμό στόματος και στομάχου από το ελικοβακτηρίδιο του πυλωρού (H. Pylori): η συμβολή της αγωγής εκρίζωσης του μικροβίου στην αντιμετώπιση της περιοδοντικής νόσου
Abstract
dc:descriptionBackground & Aims: Periodontitis is the leading cause of tooth loss and advanced periodontitis is the sixth commonest disease worldwide, with a prevalence of 10.8% to 11.2%. It is a chronic inflammatory disease of the periodontal tissues due to anaerobic Gram (-) bacteria. The advanced form of the disease is characterized by progressive alveolar bone destruction resulting in the formation of a periodontal pocket and gum retraction. Periodontitis can be considered as the disruption of homeostatic mechanisms that balance the oral biofilm microflora and the host defense mechanisms, while has been associated with cardiovascular disease, certain types of cancer, type 2 diabetes, renal disease, respiratory disease and pregnancy complications.Helicobacter Pylori (H. pylori), first reported in 1983, is a microaerophilic Gram (-) spiral-helical bacterium adapted to survive in the gastric acidic environment, neutralizing it by secreting urease. Although gastric H. pylori infection has a worldwide prevalence of 44.3%, a higher prevalence exists in developing countries (50.8%) compared with the developed ones (34.7%). Gastric mucosal infection by H. pylori has been associated with gastritis, gastric and duodenal ulcers and gastric cancer. In addition, H. pylori infection has associated with several non-peptic diseases, such as coronary heart disease and cardiovascular disease, iron deficiency anemia, diabetes mellitus, neurological diseases, pregnancy complications, laryngeal diseases, skin diseases and eye diseases. Finally, H. pylori infection has been associated with oral cavity diseases, such as recurrent aphthous stomatitis, halitosis, burning mouth syndrome, lingual hyperplasia and oral lichen planus.Treatment of H. pylori infection is by combinations of antibiotics together with proton pump-inhibitors (PPI), taken simultaneously or sequentially, for 7 to 14 days. However, in clinical practice, no treatment guarantees H. pylori eradication. The high rates of H. pylori infection recurrence led researchers to investigate whether the oral cavity is an extra-gastric H. pylori reservoir, as systemic antimicrobials against H. pylori fail to disrupt the germ-protective oral biofilm. Studies have demonstrated the permissive role of chronic periodontal disease in the colonization of the oral cavity and gastric infection by H. pylori. The aim of the present study is: 1) To assess the prevalence of salivary and gastric H. pylori infection in patients with and without periodontitis; 2) to assess the prevalence of H. pylori infection in patients with periodontitis according to the clinical classification of the latter; 3) to evaluate the effect of periodontitis treatment in patients with or without gastric H. pylori infection; and 4) to evaluate if gastric H. pylori eradication treatment in patient with H. pylori infection treatment in combination with periodontitis treatment influences periodontitis clinical outcome.Methods: Thirty-three patients (age 55.5 ± 12.4 years) with stage ≥2 periodontitis treated by quadrant scaling and root planning (QSRP) for 4 weeks. The simplified plaque index (PI- presence or absence of supragingival plaque using basic fuchsin as a disclosing agent), presence or absence of bleeding on probing index (BOP), probing pocket depth (PPD- distance from the gingival margin to the bottom of the gingival sulcus, in mm) and clinical attachment level (CAL- distance from the cementoenamel junction to the bottom of the gingival sulcus, in mm) were assessed on 6 sites per tooth, pre- and 3 months post-treatment. Patients with PPD ≥4 mm and/or CAL ≥4 mm >30% of the measurement surfaces and BOP >10% were classified into the test group (n = 33), while those with BOP <10% and PPD ≤3 mm were classified into the control group (n = 32). The patients were tested for oral and gastric H. pylori and, in the case of gastric infection, received eradication therapy for 10 days (dual therapy including a PPI plus amoxicillin 1 g twice daily both, for the first 5 days followed by a triple therapy including a PPI, clarithromycin 500 mg and metronidazole 500 mg twice daily all, for the remaining 5 days). The control group of 32 periodontically healthy volunteers (age 55.5 ± 13.4 years) were tested for oral and gastric H. pylori too. Saliva samples were evaluated by real-time polymerase chain reaction (rtPCR); gastric H. pylori was detected by Urea Breath Test (UBT).Results: No saliva samples were positive for H. pylori. Gastric H. pylori was detected in 6 patients with periodontitis and 7 controls (p >0.05). H. pylori infection affected patients with higher disease stage and grade. H. pylori (+) patients presented with higher disease severity for staging (χ2 = 11.873, p = 0.003) and grading (χ2 = 7.792, p = 0.02). All H. pylori (+) patients underwent successful eradication treatment. All clinical periodontitis indices improved following QSRP. H. pylori (+) patients who received QSRP as adjunctive to eradication treatment showed improvement in BOP (p <0.001), PI (p <0.013) and CAL (p <0.004) compared with H. pylori (-) patients who received QSRP alone. In particular H. pylori (+) patients showed: BOP 82.18% improvement vs 58.04% of H. pylori (-), PI 76.72% improvement vs to 52.69% of H. pylori (-), PPD 33.13% improvement vs 24.43% of H. pylori (-) and CAL 6.6% vs 0.22% of H. pylori (-).Conclusions: Periodontitis was not associated to gastric H. pylori infection, and saliva was not a gastric H. pylori supply reservoir. Gastric H. pylori infection was associated with advanced stages and degrees of periodontitis when the two conditions coexist. Although the periodontal clinical markers improved after QSRP regardless of gastric HP infection status, BOP, PI and CAL were further improved when combined with eradication treatment. Periodontal evaluation and treatment combined with H. pylori eradication is recommended in patients with gastric H. pylori (+) infection.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsimpiris, Athanasios
- Τσιμπιρής, Αθανάσιος
Subjects
dc:subject × 18- Περιοδοντίτιδα
- Ελικοβακτηρίδιο πυλωρού
- Σάλιο
- Στοματική κοιλότητα
- Θεραπεία εκρίζωσης
- Περιοδοντική θεραπεία
- Periodontitis
- Helicobacter pylori
- Saliva
- Oral cavity
- Eradication therapy
- Periodontal treatment
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Γαστροεντερολογία
- Clinical Medicine
- Medical and Health Sciences
- Gastroenterology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51518